433.03
0.43 (0.10%)
| Previous Close | 432.60 |
| Volume | 296,514 |
| Price / Earnings (Forward) | 62.24 |
| Price / Sales | 6.99 |
| Price / Book | 16.02 |
| 52 Weeks Range |
| Profit Margin | -123.38% |
| Operating Margin (TTM) | -57.79% |
| Diluted EPS (TTM) | -17.83 |
| Total Debt/Equity (MRQ) | 16.85% |
| Current Ratio (MRQ) | 5.91 |
| Operating Cash Flow (TTM) | -395.31 M |
| Levered Free Cash Flow (TTM) | -274.11 M |
| Return on Assets (TTM) | -25.56% |
| Return on Equity (TTM) | -50.16% |
AIStockmoo Score
| Value 30% | 0.0 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Return on Capital info | NA |
| Timing 30% | -1.4 |
| From our AI technical analysis of the chart. info | NA |
| No clear trend over the past year. Far below its 52-week high. info | |
| Recent bearish reversal pattern: Shooting star. info | |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| News Mood info | NA |
| Smart Money 20% | 1.1 |
| Insiders net buying recently. info | |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Price is low against its 52-week average. Up over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| Price is between support and resistance. info | |
| Final Score | -0.20 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Madrigal Pharmaceuticals, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| MDGL | - | - | - | 16.02 |
| FOLD | 5 B | - | - | - |
| IGMS | 71 M | - | - | 0.760 |
| SLGL | - | - | - | 3.80 |
| ACAD | - | - | - | 2.34 |
| COGT | - | - | - | 11.00 |
Select this tab to load the latest available analysis.
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 7.73% |
| % Held by Institutions | 108.28% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 399.77 | - | 91,806 | 36,700,965 |
| KELLEY SHANNON T | - | 399.63 | -1,077 | -430,402 |
| Aggregate Net Quantity | 90,729 | |||
| Aggregate Net Value ($) | 36,270,563 | |||
| Aggregate Avg. Buy ($) | 399.77 | |||
| Aggregate Avg. Sell ($) | 399.63 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KELLEY SHANNON T | Officer | 06 Nov 2026 | Automatic sell (-) | 1,077 | 399.63 | 430,402 |
| BAKER BROS. ADVISORS LP | Director | 06 Nov 2026 | Buy (+) | 76,140 | 399.63 | 30,427,828 |
| BAKER BROS. ADVISORS LP | Director | 04 Nov 2026 | Buy (+) | 15,666 | 400.43 | 6,273,136 |
Recent Signals candle patterns and EMA crosses
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |